异基因造血干细胞移植(hematopoietic cell transplantation, HCT)是多种恶性和非恶性疾病的重要且有治愈可能的治疗选择。但**矛盾地是，为成功进行异基因HCT所设计的减瘤预处理方案总体上不利于免疫系统的恢复，特别是淋巴细胞的产生。**

免疫系统恢复延迟与并发症发生率和死亡率较高相关[[1-3](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/1-3)]。**移植后免疫耗竭在T细胞系尤为明显，而T细胞系对负调节极其敏感，胸腺功能随年龄而明显下降可证实这一点** 。其结果是，免疫系统重建远远不能满足临床需求。临床前研究和临床研究已发现了对无效淋巴细胞增殖和移植后免疫缺陷有前景的数种治疗策略。

本文将讨论异基因HCT后免疫重建。HCT后免疫和HCT相关的其他支持治疗详见其他专题。(参见 [“造血干细胞移植候选者和移植受者的免疫接种”](https://www.uptodate.cn/contents/zh-Hans/immunizations-in-hematopoietic-cell-transplant-candidates-and-recipients?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“造血干细胞移植后的造血支持”](https://www.uptodate.cn/contents/zh-Hans/hematopoietic-support-after-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“造血干细胞移植的早期并发症”](https://www.uptodate.cn/contents/zh-Hans/early-complications-of-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

文中“HCT”是统称，包含任何来源的祖细胞移植，如骨髓(bone marrow, BM)、外周血、脐带血(umbilical cord blood, UCB)。其他情况下，这些细胞的来源将作具体说明(例如外周血祖细胞移植)。

**免疫重建概述化疗和/或放疗作为预处理(或准备)方案是异基因HCT的关键部分，目的在于产生充分的免疫抑制以避免移植物排斥反应。烷化剂化疗和放疗均以高度增殖的细胞为目标[[4-6](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/4-6)]，包括发育中及初始淋巴细胞[[1](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/1)]。这会导致移植后免疫系统中所有造血细胞均严重消耗，尤其是淋巴细胞。** (参见 [“造血干细胞移植的预处理方案”](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

**固有(天然)和适应性免疫系统在移植后逐渐恢复。固有免疫系统常在移植后数月内恢复。而适应性免疫系统重建需要1-2年。免疫重建的时机受移植过程中许多变量的影响，如具体预处理方案、供者类型、造血祖细胞来源以及移植物抗宿主病(graft-versus-host disease, GVHD)的预防措施** ，见下文。(参见下文[‘移植特征对免疫重建的影响’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875541))

以下章节将概述移植后固有和适应性免疫的重建，固有和适应性免疫详见其他专题。(参见 [“固有免疫系统概述”](https://www.uptodate.cn/contents/zh-Hans/an-overview-of-the-innate-immune-system?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“适应性体液免疫应答”](https://www.uptodate.cn/contents/zh-Hans/the-adaptive-humoral-immune-response?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“适应性细胞免疫应答：T细胞和细胞因子”](https://www.uptodate.cn/contents/zh-Hans/the-adaptive-cellular-immune-response-t-cells-and-cytokines?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

固有免疫 — 固有(天然)免疫是指机体与生俱来的免疫应答，并不是通过暴露于微生物而习得、适应或持久加强的免疫。固有免疫有两个基本组成部分[[7-9](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/7-9)]：

●非造血细胞系，包括物理屏障，如皮肤和黏膜表面

●造血细胞，包括中性粒细胞、巨噬细胞以及自然杀伤(natural killer, NK)细胞

尽管非造血部分的固有免疫会受到预处理(准备)方案(如化疗和/或放疗)的影响，但在HCT后往往迅速恢复[[10](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/10)]。**应注意，当GVHD累及皮肤和黏膜表面时，这些物理屏障的修复会延迟。** (参见 [“急性移植物抗宿主病的临床表现、诊断和分级”，关于‘临床和组织学表现’一节](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease?sectionName=%E4%B8%B4%E5%BA%8A%E5%92%8C%E7%BB%84%E7%BB%87%E5%AD%A6%E8%A1%A8%E7%8E%B0&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H3&source=see_link#H3))

**HCT后首先植活的造血细胞是单核细胞，其次是粒细胞、血小板和NK细胞[[10](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/10)]。中性粒细胞计数可在2-4周内恢复正常，而其功能可能长达4个月未能完全恢复[[11](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/11)]。尽管巨噬细胞不会因移植预处理明显消耗，但在HCT后数月其逐渐被供者来源的巨噬细胞所替代[[12](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/12)]。单核细胞功能可能在长达1年的时间未能完全恢复[[13,14](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/13,14)]。NK细胞的数量和功能在HCT后数周均可恢复[[15-17](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/15-17)]。

适应性免疫 — 适应性免疫是通过B淋巴细胞和T淋巴细胞实现的，在人的一生都会不断地完善和调整。HCT后，供者来源的T和B淋巴细胞必须重建细胞和体液免疫应答系统。

●针对病原体的细胞免疫应答由抗原提呈细胞(如树突细胞)启动，需要功能T细胞的活化。(参见 [“适应性细胞免疫应答：T细胞和细胞因子”](https://www.uptodate.cn/contents/zh-Hans/the-adaptive-cellular-immune-response-t-cells-and-cytokines?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

●体液免疫应答由抗体介导，需要功能B细胞(浆细胞、记忆细胞)和功能T细胞共同作用。(参见 [“适应性体液免疫应答”](https://www.uptodate.cn/contents/zh-Hans/the-adaptive-humoral-immune-response?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

这些系统的完全恢复需要数年，特别是有慢性GVHD时。(参见 [“移植物抗宿主病的发病机制”](https://www.uptodate.cn/contents/zh-Hans/pathogenesis-of-graft-versus-host-disease-gvhd?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

**适应性细胞免疫的恢复 — 适应性免疫系统在HCT后严重受损，主要由于初始T细胞减少及现存T细胞功能减退[[18-25](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/18-25)]。CD4:CD8比值出现倒置，表现为CD4+ T细胞水平降低而CD8+ T细胞水平正常或升高** [[26](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/26)]。

T细胞免疫可通过两条独立途径恢复[[1,27](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/1,27)]：

●**输注供者记忆T细胞后在外周扩增，形成狭窄的T细胞受体(T cell receptor, TCR)库**

●**输注供者造血祖细胞后种植于胸腺，随后生成多样性初始TCR库** 

对于接受不去T细胞移植物的患者，输注的记忆T细胞在外周扩增，产生最初较窄的TCR库，随后当胸腺种植的造血祖细胞生成初始T细胞时，TCR库就开始扩大。后一种机制是稳定状态下T细胞发育的主要途径，且理论上是去T细胞移植情况下T细胞恢复的唯一机制。相反，无功能性胸腺的患者以前一种机制为主。

因此，**HCT后T细胞的有效重建需要有功能的胸腺，尤其是对CD4+ T细胞[[28](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/28)]。HCT后依赖胸腺产生有效T细胞库对于老年患者是重要障碍，因为这些患者的胸腺通常已经萎缩[[29](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/29)]。和儿童相比，胸腺已经萎缩的成年患者在化疗或HCT之后，恢复能力显著受损[[18,24,27,30](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/18,24,27,30)]。而年轻患者和年老患者的CD8+ T细胞恢复均相对较快[[31](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/31)]，因为CD8+ T细胞主要来源于胸腺外的克隆扩增[[32,33](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/32,33)]。胸腺随年龄而退化可以解释为何中年或更年轻的患者有可能完全恢复免疫，而老年患者的外周初始TCR库始终不能完全恢复[[34](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/34)]，并且感染发生率与CD4 T细胞计数偏低直接相关** [[35](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/35)]。(参见下文[‘供者和受者特征’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6268181))

体液免疫应答的恢复 — 体液免疫应答由抗体介导，同时需要功能B细胞(浆细胞、记忆细胞)和功能T细胞。除上文介绍的HCT后T细胞恢复延迟外，**HCT后B细胞系的重建也明显受损[[36,37](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/36,37)]。除了导致对病原体应答受损之外，体液免疫应答受损理论上还可导致疾病复发或第二恶性肿瘤** [[38-40](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/38-40)]。

**和T细胞相似，HCT移植后B细胞立即完全消耗，但自体移植后6个月或是异基因移植后9个月可达到正常水平[[41](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/41)]。和TCR库很相似，B细胞抗体库也严重减少并且恢复期很长[[42](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/42)]。异基因HCT后，B细胞重建受损主要是因为GVHD及其治疗药物(特别是大剂量皮质类固醇和免疫抑制剂)**[[43](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/43)]。(参见下文[‘GVHD’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H21151647)和 [“慢性移植物抗宿主病的治疗”](https://www.uptodate.cn/contents/zh-Hans/treatment-of-chronic-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

免疫重建检测现在一致认为，移植后应常规检测免疫球蛋白滴度。我们和其他学者还认为，应在HCT后1年检测CD4细胞计数作为总体适应性免疫功能的评估内容[[44](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/44)]。应注意，淋巴细胞或免疫球蛋白水平恢复至正常值并不一定代表免疫功能正常。(参见 [“免疫系统的实验室评估”](https://www.uptodate.cn/contents/zh-Hans/laboratory-evaluation-of-the-immune-system?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“免疫系统的实验室评估”，关于‘先进的检查’一节](https://www.uptodate.cn/contents/zh-Hans/laboratory-evaluation-of-the-immune-system?sectionName=%E5%85%88%E8%BF%9B%E7%9A%84%E6%A3%80%E6%9F%A5&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H4354648&source=see_link#H4354648)和 [“免疫系统的实验室评估”，关于‘T细胞功能增殖检测’一节](https://www.uptodate.cn/contents/zh-Hans/laboratory-evaluation-of-the-immune-system?sectionName=T%E7%BB%86%E8%83%9E%E5%8A%9F%E8%83%BD%E5%A2%9E%E6%AE%96%E6%A3%80%E6%B5%8B&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H8&source=see_link#H8)和 [“原发性免疫缺陷的新生儿筛查”，关于‘TREC筛查试验’一节](https://www.uptodate.cn/contents/zh-Hans/newborn-screening-for-primary-immunodeficiencies?sectionName=TREC%E7%AD%9B%E6%9F%A5%E8%AF%95%E9%AA%8C&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H114056780&source=see_link#H114056780))

目前尚无评估免疫重建的理想指标。临床研究采用的是以下一项或多项指标：

●总体生存和无病生存情况

●临床感染或经培养证实的感染

●淋巴细胞绝对计数

●CD4细胞绝对计数

●CD4/CD8细胞比例

●流式细胞术检测T细胞亚群(如，检测CD45RA，其是初始CD4+ T细胞的标记物)

●免疫球蛋白水平–血清IgG水平

●接种疫苗后抗原特异性抗体滴度的上升情况

●高级体外试验检测B或T细胞功能，例如测定丝裂原诱导活化，或是定量检测T细胞受体重排删除环(T cell receptor rearrangement excision circles, TREC)，其与新形成的抗原特异性T细胞有关

●TCR谱型测定，评估受体库的多样性

●对T细胞受体深度测序以评估T细胞库

其中体液免疫重建最可靠的指标可能是接种疫苗或发生感染后，抗原特异性抗体水平升高幅度有临床意义[[44](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/44)]。此外，对于HCT受者和HIV感染者，CD4细胞计数升高可使其感染风险下降并改善结局。一项研究显示，移植后3个月时CD4 T细胞计数＜200/μL与感染增加、非复发死亡率增加和总生存率下降有关[[45](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/45)]。应注意，血清IgG水平可能反映预处理后仍存活的浆细胞，或是反映B细胞重建[[44](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/44)]。

移植特征对免疫重建的影响如上所述，固有(天然)和适应性免疫系统在移植后逐渐恢复。移植过程中的很多因素都会影响免疫重建的时机，例如干细胞来源、人类白细胞抗原(human leukocyte antigen, HLA)和次要组织相容性抗原的匹配程度、所用预处理方案、移植前对移植物的任何处理、免疫抑制治疗(尤其是皮质类固醇)以及是否发生GVHD。鉴于移植过程很复杂，不可能定量评估任一因素对植活的影响，所有因素协同影响免疫重建。

供者和受者特征 — 选择异基因HCT供者的方法有多种。以下因素对决定选择何种类型供者有重要影响：基础疾病、供受者总体健康状况、感染史、移植中心的临床方法等等。需注意，供者特征可能影响免疫重建的时机，如HLA不匹配程度及供者年龄。

●**HLA不匹配**—虽然大多数移植中心优选HLA相合同胞供者，但估计仅约有25%的患者有HLA相合的亲缘供者[[46](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/46)]。无HLA相合同胞的患者可选择以下供者：HLA相合的非亲缘供者、单个抗原不匹配的亲缘供者、相匹配或不匹配的脐血(umbilical cord blood, UCB)，或是单倍体相合供者。与采用其他供者的HCT相比，采用HLA相合亲缘供者的HCT移植后成功恢复免疫的可能性最高[[46,47](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/46,47)]。更高与采用非亲缘供者或HLA不匹配的HCT受者相比，采用HLA相合HCT受者的感染性并发症发生率[[48-50](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/48-50)]。**然而，越来越多通过使用移植后[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)[[51](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/51)]或TCRα/β特异性抗体去除离体T细胞[[52](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/52)]的半相合HCT数据显示，T细胞重建的速度令人惊喜。** (参见 [“造血干细胞的来源”](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

●**供者年龄**–随着供者年龄增加，造血干细胞功能缺陷似乎会逐渐加重，细胞系分化潜能偏离淋系细胞而转向髓系前体细胞[[53-56](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/53-56)]。此外，研究表明年老供者的造血干细胞植活能力和总体重建潜能下降[[57-59](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/57-59)]。因此，最早从36岁起，供者年龄增加会影响HCT的结局[[60-62](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/60-62)]。(参见 [“造血干细胞移植的供者选择”，关于‘供者特征的影响’一节](https://www.uptodate.cn/contents/zh-Hans/donor-selection-for-hematopoietic-cell-transplantation?sectionName=%E4%BE%9B%E8%80%85%E7%89%B9%E5%BE%81%E7%9A%84%E5%BD%B1%E5%93%8D&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H91588723&source=see_link#H91588723))

●受者年龄–针对小鼠和人类的研究表明，在全身放疗和预处理化疗后，胸腺上皮微环境严重受损，导致T细胞发育受损[[63-71](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/63-71)]。虽然既往认为胸腺微环境相对静止，但现已证实其存在缓慢而持续的变迁，并且随年龄增长逐渐萎缩[[72](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/72)]。HCT后胸腺功能的恢复主要取决于受者年龄。年轻患者的胸腺功能远期恢复不受影响，减瘤治疗导致的上皮细胞损伤最终会恢复[[27,73](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/27,73)]。而对于胸腺随年龄增长已明显退化的年长个体，减瘤预处理所致的胸腺损伤尤其不利[[74](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/74)]。虽然早在1岁就可观察到胸腺老化[[75](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/75)]，但青春期后才会明显观察到年龄对免疫重建的显著影响[[27,28,76](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/27,28,76)]。这一问题见上文。(参见上文[‘适应性细胞免疫的恢复’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875527))

●**巨细胞病毒状态–巨细胞病毒(cytomegalovirus, CMV)阳性受者有CMV再激活的风险，HCT后移植相关死亡率可能升高。这种情况下，CMV再激活会导致CMV特异性CD8+效应性记忆T细胞扩增，导致更加多样性的T细胞库重建延迟** [[77](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/77)]。HCT后CMV再激活风险详见其他专题。(参见 [“造血干细胞移植受者的病毒感染预防”，关于‘CMV的风险’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-viral-infections-in-hematopoietic-cell-transplant-recipients?sectionName=CMV%E7%9A%84%E9%A3%8E%E9%99%A9&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H344612705&source=see_link#H344612705))

造血干细胞来源 — 用于HCT的造血干细胞有几种来源，其选择可能影响HCT后免疫重建。有关干细胞来源对免疫重建影响的数据主要来源于回顾性研究和非随机性前瞻性试验。

●**骨髓**–过去，骨髓(bone marrow, BM)是HCT中最常用的干细胞来源。输注骨髓后，固有免疫常在数月间恢复。而适应性免疫的重建需1-2年，该内容见上文。(参见上文[‘免疫重建概述’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875504))

●**外周血祖细胞**–现已广泛使用经过动员的外周血祖细胞(peripheral blood progeitor cell, PBPC)作为干细胞来源，主要是由于外周血采集便利。然而，接种液中PBPC移植物的T细胞约是骨髓的10倍[[78](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/78)]，导致慢性GVHD的风险增加[[79,80](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/79,80)]。虽然骨髓来源干细胞的归巢能力稍优于PBPC[[81](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/81)]，但是PBPC植活(以血小板和中性粒细胞重建为指标)明显更快[[80](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/80)]。目前认为主要原因在于，与骨髓移植物相比，PBPC移植物的长期重建干细胞相对较少，而定向多能祖细胞相对较多[[80](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/80)]。(参见 [“造血干细胞的来源”，关于‘用于恶性疾病的PBPC VS 骨髓’一节](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?sectionName=%E7%94%A8%E4%BA%8E%E6%81%B6%E6%80%A7%E7%96%BE%E7%97%85%E7%9A%84PBPC+VS+%E9%AA%A8%E9%AB%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H16&source=see_link#H16))

●**脐血–**脐血富含造血干细胞，也可用作为干细胞来源。最初脐血未能广泛用于HCT的主要障碍在于单个供者能采集的脐血量有限。在成人中，现在通过移植双份部分匹配的非亲缘脐血移植物(双份脐血移植)至少部分解决了该问题[[82](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/82)]。双份脐血移植后，一份移植物主要负责远期重建，而另一份则介导短期植活[[83,84](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/83,84)]。与无亲缘供者骨髓移植或动员后的PBPC移植相比，脐血移植后中性粒细胞减少的中位时间更长(约30日 vs 14日)、获得性免疫重建延迟和感染相关并发症发生率增加[[85-87](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/85-87)]。但感染相关死亡似乎未增加。(参见 [“采用清髓性和非清髓性预处理方案进行成人脐带血移植”，关于‘毒性和移植相关死亡’一节](https://www.uptodate.cn/contents/zh-Hans/umbilical-cord-blood-transplantation-in-adults-using-myeloablative-and-nonmyeloablative-preparative-regimens?sectionName=%E6%AF%92%E6%80%A7%E5%92%8C%E7%A7%BB%E6%A4%8D%E7%9B%B8%E5%85%B3%E6%AD%BB%E4%BA%A1&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H426439939&source=see_link#H426439939))

移植物处理和干细胞剂量 — 造血干细胞移植物采集后，要评估确定预计的干细胞剂量。某些移植物在输注前还要经过去T细胞处理或富集造血干细胞处理。干细胞剂量和移植物处理会影响移植后免疫重建的速度。

●**干细胞剂量**–输注的造血干细胞量会影响HCT后造血恢复的速度[[88](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/88)]。根据干细胞的测定方法和来源不同，获得快速且稳定的远期植活所需的剂量各不相同。该内容详见其他专题。(参见 [“造血干细胞的来源”，关于‘骨髓’一节](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?sectionName=%E9%AA%A8%E9%AB%93&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H6&source=see_link#H6)和 [“造血干细胞移植中脐血移植物的选择”，关于‘细胞数量’一节](https://www.uptodate.cn/contents/zh-Hans/selection-of-an-umbilical-cord-blood-graft-for-hematopoietic-cell-transplantation?sectionName=%E7%BB%86%E8%83%9E%E6%95%B0%E9%87%8F&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H61604500&source=see_link#H61604500)和 [“造血干细胞的来源”，关于‘最佳CD34细胞数量’一节](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells?sectionName=%E6%9C%80%E4%BD%B3CD34%E7%BB%86%E8%83%9E%E6%95%B0%E9%87%8F&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H202139739&source=see_link#H202139739))

●**去除T细胞**–一些中心采用T细胞去除或造血干细胞富集来处理干细胞移植物，以试图降低GVHD的发生率。虽然这些技术可在主要和次要组织相容性屏障的情况下可有效地预防急性GVHD，但是从供者骨髓中去除T细胞可能对植活率、免疫重建的充分性以及白血病复发率或感染发生率产生不良影响。对于年轻和年老受者，去除异基因移植物中的T细胞可导致免疫重建显著延迟，并引起感染相关并发症发生率和死亡率均升高[[89-91](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/89-91)]。相反地，几项小型研究表明，移植物中调节性T细胞(regulatory T cell, Treg)数量较多可改善免疫重建、减少GVHD及巨细胞病毒感染[[92-95](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/92-95)]。(参见 [“移植物抗宿主病的预防”，关于‘体内TCD’一节](https://www.uptodate.cn/contents/zh-Hans/prevention-of-graft-versus-host-disease?sectionName=%E4%BD%93%E5%86%85TCD&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H263518593&source=see_link#H263518593))

预处理和免疫抑制 — 预处理(即准备)方案旨在产生充分的免疫抑制，以便预防移植物排斥。目前有多种预处理方案，包括使用化疗药物(如[环磷酰胺](https://www.uptodate.cn/contents/zh-Hans/92845?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和[白消安](https://www.uptodate.cn/contents/zh-Hans/92846?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))和/或全身放疗[[47](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/47)]。小鼠模型研究表明，较高强度预处理方案可显著提高非亲缘不匹配移植物的植活率，但也会增加治疗相关毒性[[96](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/96)]。

**预处理方案分为清髓性、减低强度和非清髓性。已提出了这3种预处理方案的定义，但未达成共识。清髓性方案使用单药或多药联合治疗，以期破坏受者骨髓中的造血细胞并引起严重全血细胞减少。这种全血细胞减少是持久且很可能不可逆的，对大多数病例是致命的，除非输注造血干细胞恢复造血。而减低强度或非清髓性预处理不会彻底消除宿主的造血恢复能力** 。(参见 [“造血干细胞移植的预处理方案”，关于‘定义’一节](https://www.uptodate.cn/contents/zh-Hans/preparative-regimens-for-hematopoietic-cell-transplantation?sectionName=%E5%AE%9A%E4%B9%89&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H2&source=see_link#H2))

**如上所述，胸腺负责产生多样性初始TCR库。HCT后，输注的供者造血祖细胞在胸腺种植，这对重建适应性细胞免疫应答十分重要。尽管清髓性、减低强度和非清髓性预处理方案均可损伤胸腺，但尚不清楚损伤程度是否随预处理强度不同而异。非清髓性预处理后免疫重建的动力学尚未完全明确，但推测可能比清髓性预处理的早期恢复更快，但两种方案后期免疫功能恢复速度相近** [[10](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/10)]。

还需注意，用于HCT植活和干细胞动员的预处理方案对造血干细胞功能也有影响。尽管静止期造血干细胞数量大多不受很多化疗和小剂量放疗方案的影响[[97](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/97)]，但是其造血功能仍严重受损[[98,99](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/98,99)]。这些细胞会出现加速衰老，并伴随细胞周期蛋白依赖性激酶抑制剂p19Arf和p16ink4A的上调[[100,101](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/100,101)]，类似于随年龄增长所见的某些影响。

GVHD — 急性和慢性GVHD及其治疗会显著延迟免疫重建。过去以时间为基础来界定慢性GVHD(即，HCT后100日之后)，但现在强调的是病理生物学[[102](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/102)]。早在HCT后50日即可出现符合慢性GVHD的临床特征[[102](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/102)]，而急性GVHD表现可能在HCT后数月才出现，特别是经过非清髓性预处理后，甚至可和慢性GVHD的表现重叠[[103](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/103)]_。_(参见 [“急性移植物抗宿主病的临床表现、诊断和分级”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-diagnosis-and-grading-of-acute-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)和 [“慢性移植物抗宿主病的临床表现和诊断”](https://www.uptodate.cn/contents/zh-Hans/clinical-manifestations-and-diagnosis-of-chronic-graft-versus-host-disease?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

GVHD可累及皮肤和黏膜表面，这两者是固有(天然)免疫系统的非造血细胞系部分。预处理对这些部位的损伤通常可在HCT后快速恢复。但如果GVHD累及皮肤和黏膜，这些物理屏障的修复则可能延迟。

慢性GVHD患者的体液和细胞介导免疫均显著受损，抗原提呈细胞重建延迟，且脾功能减退。由于移植物抗宿主浆细胞/朗格汉斯细胞作用，急性GVHD患者的浆细胞和树突状细胞计数的最低值降低[[10,104](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/10,104)]。单核细胞可能需要长达1年才能恢复功能，组织树突状细胞(如朗格汉斯细胞)的数量和功能恢复可能需要长达6个月。使用全身性皮质类固醇和其他免疫抑制剂治疗慢性GVHD时，将进一步阻碍免疫重建和对疫苗的免疫应答[[105](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/105)]。此外，胸腺对用于抑制免疫系统以减轻GVHD影响的治疗以及GVHD本身非常敏感[[106-110](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/106-110)]。

改善免疫重建的治疗策略

概述 — 人们已提出多种促进HCT后免疫重建的策略。虽然已进行了临床前研究的策略很多，但是用于临床的很少。提出的策略包括：外源性给予细胞因子和激素[(如角化细胞生长因子(keratinocyte growth factor, KGF)、白细胞介素-7(interleukin-7, IL-7)]、性类固醇激素去除(sex steroid ablation, SSA)、输注淋系前体细胞以及培育异位胸腺组织等。胸腺基质和造血细胞系之间的交互作用提示，相比任何单一策略而言，联合应用针对不同通路(促胸腺细胞生成)策略的促再生作用更好。这些策略见下文。

联合针对不同通路的策略很可能取得成功。例如，有人提出KGF联合前体淋巴细胞输注[[111](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/111)]、SSA[[69](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/69)]或p53暂时抑制[[70](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/70)]可能会取得成功。而IL-7联合KGF或SSA不太可能有效促进胸腺细胞生成，因为后两种策略都是促进胸腺内合成IL-7，而基因敲除小鼠研究表明这些再生策略均依赖IL-7[[112,113](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/112,113)]。

发育中的T细胞与支持性胸腺基质微环境的相互作用对正常胸腺功能至关重要，有研究利用这一点极大地促进了胸腺再生。然而，探索利用骨髓与胸腺之间的基本关系来促进免疫重建的研究则少很多，而这一基本关系主要取决于前体淋巴细胞的供应。虽然自骨髓释放而种植于胸腺的循环祖细胞准确系别尚不清楚[[114-118](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/114-118)]，但这些细胞具有改善免疫重建这一潜力是很明确的[[119](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/119)]。造血干细胞功能的根本缺陷，特别是沿淋系向下分化的能力缺陷[[120](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/120)]，可能会促成胸腺出现年龄相关的某些改变[[121](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/121)]。然而，至少关于年龄相关胸腺发育不全的研究发现，仅改善干细胞功能不足以恢复胸腺细胞的生成[[122](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/122)]，减少祖细胞的输入也不足以导致胸腺退化[[123](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/123)]。这提示这些造血干细胞功能缺陷只是促成而非导致了年龄相关的淋巴细胞生成减少。

细胞因子和激素 — 人们已提出多种促进HCT后免疫重建的策略。虽然已进行了临床前研究的策略很多，但是用于临床的很少。提出的策略包括外源性给予细胞因子和激素，模型研究发现其能恢复淋巴细胞生成作用。其中KGF、IL-7、Flt-3配体(Flt-3 ligand, Flt3L)以及生长激素(growth hormone, GH)均有望恢复淋巴细胞生成的能力。

●**KGF**—动物模型研究发现，对年老和放疗或化疗后的动物外源性地给予KGF后，胸腺细胞数目增加至对照组的4倍[[112,124,125](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/112,124,125)]。此外，KGF可让胸腺上皮细胞(thymic epithelial cells, TEC)免受GVHD介导的胸腺损伤[[125](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/125)]，KGF引起的胸腺细胞生成作用是通过TEC的增殖和扩增介导的[[126](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/126)]。虽然美国FDA批准KGF用于预防大剂量化疗患者(包括HCT患者)发生黏膜炎，但目前尚无关于KGF促进患者T细胞重建潜能的临床数据。

●**IL-7**–促淋巴细胞生成的细胞因子IL-7能够直接作用于T淋巴细胞前体，数项研究显示IL-7可促进胸腺细胞生成。动物模型研究表明，对于年老小鼠和在异基因HCT后，IL-7可影响新近胸腺迁出细胞，并改善外周T细胞的功能[[127-131](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/127-131)]。研究显示，IL-7可逆转年龄相关凋亡增加，从而诱导胸腺再生[[132](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/132)]，同时还能促进淋巴细胞和淋系前体细胞的增殖[[127](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/127)]。动物模型和人体研究均表明，给予IL-7可使T细胞增殖，T细胞数量增加且TCR多样性增加[[133](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/133)]。一项关于重组IL-7的Ⅰ期试验纳入了12例进行去T细胞异基因HCT的成人，发现给予重组IL-7可促进T细胞恢复和T细胞库的多样性，且不增加GVHD和其他毒性[[134](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/134)]。

●**Flt3L**–**临床前研究显示，外源性Flt3L可促进胸腺依赖性和非依赖性T细胞重建[[135,136](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/135,136)]。Flt3L的作用主要是源于骨髓中Flt3+祖细胞的扩增[[137](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/137)]。然而，T细胞重建增强可能是以B淋巴细胞生成障碍为代价。一般而言，给予外源性Flt3L后，B淋巴细胞以及特别是具有淋系和髓系潜能的早期祖细胞生成显著减少** [[138,139](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/138,139)]。

●**生长激素**–外源性生长激素治疗可使已老化的胸腺再生[[140,141](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/140,141)]，并可增强骨髓造血细胞的功能[[142](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/142)]。研究还表明，生长激素能够逆转放疗相关的骨髓功能损失(通过集落形成评定)[[142](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/142)]。虽然采用生长激素促进T细胞恢复的临床经验仅限于HIV感染者，但研究表明生长激素能够显著增强该群体的胸腺功能[[143-145](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/143-145)]及抗病毒应答[[143-146](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/143-146)]。一项Ⅱ期研究评估了生长激素联合[二甲双胍](https://www.uptodate.cn/contents/zh-Hans/123175?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)的疗效，结果显示尽管未行HCT，该疗法也可能对胸腺功能有影响(NCT04375657；[[147](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/147)])。

●**IL-22–**现已确定，IL-22是急性损伤后胸腺内源性再生的重要介质[[148,149](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/148,149)]。研究证实给予外源性重组IL-22也可改善急性胸腺损伤(如全身放疗所致)后的胸腺细胞生成[[148](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/148)]，还可在暴发性GVHD时促进胸腺细胞生成[[150](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/150)]。尚无临床研究报道IL-22对免疫重建的影响，但一项Ⅰ-Ⅱ期研究(NCT02406651)正在评估IL-22治疗异基因HCT后GVHD的效果，并将评估免疫重建情况。

●**BMP4–**BMP4是在胸腺损伤时由胸腺内皮细胞产生[[151](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/151)]。BMP4通过激活转录因子FOXN1的表达，从而增强TEC支持T细胞前体细胞分化的功能。HCT实验模型显示，对胸腺内皮细胞进行细胞治疗很有前景，人们正努力将其转化至临床试验中。

有研究评估了其他几种细胞因子和生长因子在这种临床情况下的作用。[胰岛素](https://www.uptodate.cn/contents/zh-Hans/123490?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)样生长因子(insulin-like growth factor, IGF)-1能促进胸腺内皮细胞扩增，并促进HCT后重建[[152-154](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/152-154)]。IL-2能增加HCT受者Treg细胞数量并改善其功能，还可减少慢性GVHD的临床表现[[155](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/155)]。IL-15主要促进循环中NK细胞和T细胞的增殖[[156,157](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/156,157)]。IL-12能刺激胸腺表达IL-7，并促进移植后造血细胞的植活[[158-160](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/158-160)]。研究还发现，IL-15和IL-12能激活调节性淋巴组织诱导细胞和NK细胞[[161,162](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/161,162)]。甲状旁腺激素(parathyroid hormone, PTH)能够增加造血干细胞的数量[[163](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/163)]，[维A酸](https://www.uptodate.cn/contents/zh-Hans/92639?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link)能加速B淋巴细胞生成[[164](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/164)]。据报道，RANKL可促进TEC亚群的稳态分化[[165](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/165)]，在HCT小鼠模型中也能促进T细胞重建[[166](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/166)]。

性类固醇激素去除 — 雌激素和睾酮参与调节胸腺细胞生成[[167,168](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/167,168)]、B淋巴细胞生成[[169-171](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/169-171)]以及早期淋系前体细胞生成[[172,173](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/172,173)]。动物研究表明在去势或化学性雄激素阻断后胸腺功能得到改善，因此人们开始对使用SSA促进免疫重建感兴趣[[174,175](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/174,175)]。随后，人们研究了SSA对增强HCT后免疫系统的潜能。

去除年老小鼠和人体的性类固醇激素可引起胸腺结构重组并使循环祖细胞转移至胸腺[[176](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/176)]，继而增强胸腺细胞生成[[63,74,174-180](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/63,74,174-180)]。然而，SSA的作用不仅限于胸腺，还包括增强B淋巴细胞生成和淋系祖细胞生成[[121,181-185](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/121,181-185)]，以及促进自体HCT[[186](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/186)]、异基因HCT[[113](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/113)]和减瘤治疗[[63,74,185](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/63,74,185)]后的整体免疫恢复。

总之，这些研究表明SSA可改善HCT后的免疫重建。迄今为止，试验和临床数据大多仅来源于使用黄体生产素释放激素(luteinizing hormone releasing hormone, LHRH)类似物或手术SSA。更高级的LHRH拮抗剂几乎可立即停止性类固醇的合成，从而显著缩短达到SSA的时间。在广泛应用前，还需要进一步研究证实。前列腺癌患者常采用雄激素剥夺治疗。雄激素剥夺治疗的副作用详见其他专题。(参见 [“雄激素剥夺治疗的副作用”](https://www.uptodate.cn/contents/zh-Hans/side-effects-of-androgen-deprivation-therapy?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&source=see_link))

细胞治疗

前体淋巴细胞 — 实验研究表明，可从供体的骨髓中分离淋巴前体细胞，并在异基因HCT时输注给受体，以便促进HCT后T细胞的发育[[119](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/119)]。通过在离体培养系统中使用造血干细胞的Notch-1刺激，可扩增这些前体T细胞群[[111,187-189](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/111,187-189)]。应注意，前体T细胞可以跨过主要组织相容性屏障转运并继而发育为宿主耐受且功能完整的T细胞[[190](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/190)]。

临床前研究表明，与仅接受异基因造血干细胞的受者相比，经过致死性照射的HCT受者在接受过继输注前体T细胞之后，胸腺细胞数量和嵌合增加，外周T细胞和NK细胞重建也增强[[111,191,192](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/111,191,192)]。体外培养的前体T细胞除对移植后免疫重建有重要作用外，还可对其进行基因工程改造使其具有肿瘤特异性，继而用于肿瘤靶向免疫治疗[[190](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/190)]。一项Ⅰ-Ⅱ期研究(NCT04959903)将评估前体T细胞对异基因HCT后免疫重建的影响。

输注供者淋巴细胞和其他过继细胞作为免疫疗法以预防和治疗HCT后复发(或感染)，详见其他专题。(参见 [“免疫治疗在预防和治疗异基因造血干细胞移植后复发中的应用”，关于‘供者淋巴细胞输注’一节](https://www.uptodate.cn/contents/zh-Hans/immunotherapy-for-the-prevention-and-treatment-of-relapse-following-allogeneic-hematopoietic-cell-transplantation?sectionName=%E4%BE%9B%E8%80%85%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E8%BE%93%E6%B3%A8&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H3&source=see_link#H3))

人造器官和生物反应器 — 已有研究将胸腺组织移植用于先天性胸腺发育不全(如DiGeorge综合征)婴儿，但受到供者胸腺组织稀缺的限制。当下正在尝试建立异位胸腺，目前仍处于早期研发阶段。(参见 [“DiGeorge(22q11.2缺失)综合征：治疗和预后”，关于‘培养的胸腺移植’一节](https://www.uptodate.cn/contents/zh-Hans/digeorge-22q11-2-deletion-syndrome-management-and-prognosis?sectionName=%E5%9F%B9%E5%85%BB%E7%9A%84%E8%83%B8%E8%85%BA%E7%A7%BB%E6%A4%8D&search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&topicRef=16355&anchor=H23&source=see_link#H23))

数个研究小组正致力于识别和分离具有下述能力的胸腺上皮祖细胞(thymic epithelial progenitor cell, TEPC)群，即可通过改善支持性基质微环境的再生能力从而直接增强胸腺功能。虽然采用的策略不同，但目前已从胎儿胸腺中成功分离出TEPC，并将其用于培育FoxN1-/-受者的新胸腺[[193-196](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/193-196)]；目前尚未确定成人胸腺中是否存在类似细胞群[[197,198](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/197,198)]。然而，一项研究已定向将TEC重编程为多潜能的功能性皮肤干细胞[[199](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/199)]。如果采用相反方法，即将皮肤上皮重编程为TEPC，那直接移植TEPC使胸腺再生甚至是离体培育可移植胸腺的可能性就很大。

数种重建免疫的方法正在研究中，这些方法完全不依赖内源胸腺，而是注重于离体培育整个胸腺，可根据需要植入患者体内[[200,201](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/200,201)]。其中之一是去除现有胸腺的细胞，仅保留细胞外基质，并使用生物基质(biomatrices)加血管形成舱(vascularizing chambers)重建该器官。该方法的关键点是消除了阻碍异基因移植的重要免疫屏障。到目前为止，该技术已用于心脏、肝脏和肺[[202-205](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/202-205)]。

另一种方法是，将TEPC和间质成分种植到生物基质有可能离体培育出异位胸腺。一项研究采用这种方法联合可植入的促血管形成舱，成功在体内培育出了有功能的胸腺[[206](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/206)]。然而，现阶段这些方法仍需要使用TEPC启动胸腺器官形成，表明这些方法对胚胎组织的依赖以及发现成人TEPC的重要性。

总结

●**异基因造血干细胞移植后免疫重建**–异基因造血干细胞移植(HCT)后，固有(天然)免疫和适应性免疫系统将逐渐恢复。(参见上文[‘免疫重建概述’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875504))

●**HCT对免疫的其他影响**–固有免疫系统的非造血部分(如皮肤和黏膜表层)在预处理治疗时(如化疗和/或放疗)受损，但HCT后通常迅速恢复。如果移植物抗宿主病(GVHD)累及皮肤和黏膜表面，这些物理屏障的修复可能延迟。(参见上文[‘固有免疫’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875511))

●**固有免疫功能恢复**–单核细胞、粒细胞和自然杀伤(NK)细胞通常在移植后数月内恢复。中性粒细胞计数在移植后2-4周内恢复正常，但其功能可能部分受损持续长达4个月。宿主巨噬细胞在移植后数月逐渐被供者来源的巨噬细胞替代，且功能可能长达1年都不能达到最佳水平。NK细胞的数量和功能在移植后数周恢复。(参见上文[‘固有免疫’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875511))

●**适应性免疫恢复**–适应性免疫恢复通常需要1-2年，主要由于初始T细胞减少、残余T细胞功能减退以及CD4:CD8比值倒置。T细胞免疫恢复的途径有两条：输注供者记忆T细胞后在外周扩增；输注供者造血祖细胞后种植于胸腺。到HCT后9个月时，B细胞计数恢复正常水平。T细胞受体(TCR)库和B细胞抗体库均严重减少，且恢复延迟。(参见上文[‘适应性免疫’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875518))

●**影响免疫恢复的因素**–移植物来源、免疫学匹配程度、预处理方案、移植前对移植物的处理以及有无GVHD均会影响免疫重建速度。(参见上文[‘移植特征对免疫重建的影响’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875541))

●**改善免疫恢复的策略**–目前正在研究角化细胞生长因子(KGF)、IL-7、FLT-3配体(FLT3L)、生长激素(GH)及其他药物治疗，以促进异基因HCT后免疫恢复。(参见上文[‘改善免疫重建的治疗策略’](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation?search=%E9%80%A0%E8%A1%80%E5%B9%B2%E7%BB%86%E8%83%9E&source=search_result&selectedTitle=8~150&usage_type=default&display_rank=8#H6875601))

使用UpToDate临床顾问须遵循[使用条款](https://www.uptodate.cn/legal/china/license).

参考文献

1.  [Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84:2221.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/1)
2.  [Pizzo PA, Rubin M, Freifeld A, Walsh TJ. The child with cancer and infection. II. Nonbacterial infections. J Pediatr 1991; 119:845.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/2)
3.  [Mackall CL. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000; 18:10.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/3)
4.  [Brock N. The history of the oxazaphosphorine cytostatics. Cancer 1996; 78:542.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/4)
5.  [Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/5)
6.  [Trobaugh FE Jr, Husseini S. Effects of radiation on hematopoietic tissue. Am J Med Technol 1973; 39:119.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/6)
7.  [Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate and Th2 immunity. Immunol Cell Biol 2010; 88:257.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/7)
8.  [Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, et al. Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. Curr Pharm Des 2010; 16:1024.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/8)
9.  [Nochi T, Kiyono H. Innate immunity in the mucosal immune system. Curr Pharm Des 2006; 12:4203.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/9)
10.  [Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008; 30:425.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/10)
11.  [Zimmerli W, Zarth A, Gratwohl A, Speck B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood 1991; 77:393.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/11)
12.  [Nakata K, Gotoh H, Watanabe J, et al. Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation. Blood 1999; 93:667.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/12)
13.  [Cayeux S, Meuer S, Pezzutto A, et al. Allogeneic mixed lymphocyte reactions during a second round of ontogeny: normal accessory cells did not restore defective interleukin-2 (IL-2) synthesis in T cells but induced responsiveness to exogeneous IL-2. Blood 1989; 74:2278.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/13)
14.  [Sahdev I, O'Reilly R, Black P, et al. Interleukin-1 production following T-cell-depleted and unmodified marrow grafts. Pediatr Hematol Oncol 1996; 13:55.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/14)
15.  [Hokland M, Jacobsen N, Ellegaard J, Hokland P. Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation 1988; 45:1080.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/15)
16.  [Jacobs R, Stoll M, Stratmann G, et al. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 1992; 79:3239.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/16)
17.  [Vitale C, Pitto A, Benvenuto F, et al. Phenotypic and functional analysis of the HLA-class I-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors. Hematol J 2000; 1:136.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/17)
18.  [Weinberg K, Annett G, Kashyap A, et al. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant 1995; 1:18.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/18)
19.  [Roux E, Helg C, Dumont-Girard F, et al. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87:3984.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/19)
20.  [Dumont-Girard F, Roux E, van Lier RA, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998; 92:4464.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/20)
21.  [Ault KA, Antin JH, Ginsburg D, et al. Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 1985; 161:1483.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/21)
22.  [Gratama JW, Naipal A, Oljans P, et al. T lymphocyte repopulation and differentiation after bone marrow transplantation. Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease. Blood 1984; 63:1416.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/22)
23.  [Roosnek EE, Brouwer MC, Vossen JM, et al. The role of interleukin-2 in proliferative responses in vitro of T cells from patients after bone marrow transplantation. Evidence that minor defects can lead to in vitro unresponsiveness. Transplantation 1987; 43:855.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/23)
24.  [Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000; 96:2299.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/24)
25.  [Soiffer RJ, Bosserman L, Murray C, et al. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood 1990; 75:2076.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/25)
26.  [Atkinson K, Hansen JA, Storb R, et al. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets. Blood 1982; 59:1292.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/26)
27.  [Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/27)
28.  [Hakim FT, Memon SA, Cepeda R, et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005; 115:930.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/28)
29.  [Rodewald HR. The thymus in the age of retirement. Nature 1998; 396:630.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/29)
30.  [Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16:413.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/30)
31.  [Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood 1997; 89:3700.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/31)
32.  [Fagnoni FF, Lozza L, Zibera C, et al. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology 2002; 106:27.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/32)
33.  [Heitger A, Neu N, Kern H, et al. Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood 1997; 90:850.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/33)
34.  [Sfikakis PP, Gourgoulis GM, Moulopoulos LA, et al. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur J Clin Invest 2005; 35:380.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/34)
35.  [Storek J, Gooley T, Witherspoon RP, et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997; 54:131.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/35)
36.  [Storek J, Espino G, Dawson MA, et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96:3290.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/36)
37.  [Fry TJ, Mackall CL. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 2005; 35 Suppl 1:S53.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/37)
38.  [MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19:59.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/38)
39.  [von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18:574.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/39)
40.  [White CA, Weaver RL, Grillo-López AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52:125.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/40)
41.  [Storek J. B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4:423.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/41)
42.  [Li F, Jin F, Freitas A, et al. Impaired regeneration of the peripheral B cell repertoire from bone marrow following lymphopenia in old mice. Eur J Immunol 2001; 31:500.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/42)
43.  [Storek J, Wells D, Dawson MA, et al. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001; 98:489.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/43)
44.  [Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/44)
45.  [Kim DH, Sohn SK, Won DI, et al. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:1119.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/45)
46.  [Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115:3861.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/46)
47.  [Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25:139.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/47)
48.  [Hamza NS, Lisgaris M, Yadavalli G, et al. Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults. Br J Haematol 2004; 124:488.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/48)
49.  [van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant 2002; 30:303.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/49)
50.  [Yoo JH, Lee DG, Choi SM, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2004; 34:497.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/50)
51.  [Luznik L, O'Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 2012; 39:683.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/51)
52.  [Lang P, Teltschik HM, Feuchtinger T, et al. Transplantation of CD3/CD19 depleted allografts from haploidentical family donors in paediatric leukaemia. Br J Haematol 2014; 165:688.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/52)
53.  [Guerrettaz LM, Johnson SA, Cambier JC. Acquired hematopoietic stem cell defects determine B-cell repertoire changes associated with aging. Proc Natl Acad Sci U S A 2008; 105:11898.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/53)
54.  [Muller-Sieburg CE, Cho RH, Karlsson L, et al. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood 2004; 103:4111.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/54)
55.  [Signer RA, Montecino-Rodriguez E, Witte ON, et al. Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia. Blood 2007; 110:1831.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/55)
56.  [Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A 2005; 102:9194.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/56)
57.  [Kamminga LM, van Os R, Ausema A, et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells 2005; 23:82.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/57)
58.  [Kim M, Moon HB, Spangrude GJ. Major age-related changes of mouse hematopoietic stem/progenitor cells. Ann N Y Acad Sci 2003; 996:195.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/58)
59.  [Liang Y, Van Zant G, Szilvassy SJ. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 2005; 106:1479.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/59)
60.  [Carreras E, Jiménez M, Gómez-García V, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37:33.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/60)
61.  [Harrison DE, Astle CM. Loss of stem cell repopulating ability upon transplantation. Effects of donor age, cell number, and transplantation procedure. J Exp Med 1982; 156:1767.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/61)
62.  [Mehta J, Gordon LI, Tallman MS, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transplant 2006; 38:95.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/62)
63.  [Goldberg GL, Dudakov JA, Reiseger JJ, et al. Sex steroid ablation enhances immune reconstitution following cytotoxic antineoplastic therapy in young mice. J Immunol 2010; 184:6014.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/63)
64.  [Fredrickson GG, Basch RS. Early thymic regeneration after irradiation. Dev Comp Immunol 1994; 18:251.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/64)
65.  [Hauri-Hohl MM, Zuklys S, Keller MP, et al. TGF-beta signaling in thymic epithelial cells regulates thymic involution and postirradiation reconstitution. Blood 2008; 112:626.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/65)
66.  [Popa I, Zubkova I, Medvedovic M, et al. Regeneration of the adult thymus is preceded by the expansion of K5+K8+ epithelial cell progenitors and by increased expression of Trp63, cMyc and Tcf3 transcription factors in the thymic stroma. Int Immunol 2007; 19:1249.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/66)
67.  [Min D, Taylor PA, Panoskaltsis-Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99:4592.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/67)
68.  [Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood 2001; 98:1601.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/68)
69.  [Kelly RM, Highfill SL, Panoskaltsis-Mortari A, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood 2008; 111:5734.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/69)
70.  [Kelly RM, Goren EM, Taylor PA, et al. Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. Blood 2010; 115:1088.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/70)
71.  [Williams KM, Mella H, Lucas PJ, et al. Single cell analysis of complex thymus stromal cell populations: rapid thymic epithelia preparation characterizes radiation injury. Clin Transl Sci 2009; 2:279.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/71)
72.  [Gray DH, Seach N, Ueno T, et al. Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. Blood 2006; 108:3777.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/72)
73.  [Sykes M, Szot GL, Swenson K, et al. Separate regulation of peripheral hematopoietic and thymic engraftment. Exp Hematol 1998; 26:457.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/73)
74.  [Dudakov JA, Goldberg GL, Reiseger JJ, et al. Sex steroid ablation enhances hematopoietic recovery following cytotoxic antineoplastic therapy in aged mice. J Immunol 2009; 183:7084.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/74)
75.  [Flores KG, Li J, Sempowski GD, et al. Analysis of the human thymic perivascular space during aging. J Clin Invest 1999; 104:1031.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/75)
76.  [Savage WJ, Bleesing JJ, Douek D, et al. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant 2001; 28:463.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/76)
77.  [Suessmuth Y, Mukherjee R, Watkins B, et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire. Blood 2015; 125:3835.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/77)
78.  [Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/78)
79.  [Russell NH, Gratwohl A, Schmitz N. Developments in allogeneic peripheral blood progenitor cell transplantation. Br J Haematol 1998; 103:594.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/79)
80.  [Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98:2900.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/80)
81.  [Szilvassy SJ, Meyerrose TE, Ragland PL, Grimes B. Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver. Blood 2001; 98:2108.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/81)
82.  [Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/82)
83.  [Avery S, Shi W, Lubin M, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood 2011; 117:3277.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/83)
84.  [Gutman JA, Turtle CJ, Manley TJ, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 2010; 115:757.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/84)
85.  [Delaney C, Gutman JA, Appelbaum FR. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009; 147:207.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/85)
86.  [Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009; 147:246.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/86)
87.  [Kanda J, Chiou LW, Szabolcs P, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18:1664.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/87)
88.  [Chen BJ, Cui X, Sempowski GD, et al. Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation. Blood 2004; 103:4344.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/88)
89.  [Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009; 113:4114.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/89)
90.  [Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007; 109:4575.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/90)
91.  [Müller SM, Kohn T, Schulz AS, et al. Similar pattern of thymic-dependent T-cell reconstitution in infants with severe combined immunodeficiency after human leukocyte antigen (HLA)-identical and HLA-nonidentical stem cell transplantation. Blood 2000; 96:4344.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/91)
92.  [Torelli GF, Lucarelli B, Iori AP, et al. The immune reconstitution after an allogeneic stem cell transplant correlates with the risk of graft-versus-host disease and cytomegalovirus infection. Leuk Res 2011; 35:1124.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/92)
93.  [Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/93)
94.  [Gaidot A, Landau DA, Martin GH, et al. Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood 2011; 117:2975.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/94)
95.  [Winstead CJ, Reilly CS, Moon JJ, et al. CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J Immunol 2010; 184:4749.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/95)
96.  [Soderling CC, Song CW, Blazar BR, Vallera DA. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants. J Immunol 1985; 135:941.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/96)
97.  [Gardner RV, McKinnon E, Astle CM. Analysis of the stem cell sparing properties of cyclophosphamide. Eur J Haematol 2001; 67:14.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/97)
98.  [Gardner RV, McKinnon E, Poretta C, Leiva L. Hemopoietic function after use of IL-1 with chemotherapy or irradiation. J Immunol 2003; 171:1202.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/98)
99.  [Meng A, Wang Y, Brown SA, et al. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol 2003; 31:1348.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/99)
100.  [Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res 2003; 63:5414.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/100)
101.  [Wang Y, Schulte BA, LaRue AC, et al. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 2006; 107:358.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/101)
102.  [Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/102)
103.  [Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/103)
104.  Keever-Taylor. Immune reconstitution after allogeneic transplantation. In: Hematopoietic Stem Cell Transplantation, Soiffer RJ (Ed), Humana Press, Totowa, New Jersey 2008. p.377.
105.  [Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010; 24:257.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/105)
106.  [Fletcher AL, Lowen TE, Sakkal S, et al. Ablation and regeneration of tolerance-inducing medullary thymic epithelial cells after cyclosporine, cyclophosphamide, and dexamethasone treatment. J Immunol 2009; 183:823.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/106)
107.  [Purton JF, Monk JA, Liddicoat DR, et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 2004; 173:3816.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/107)
108.  [Na IK, Lu SX, Yim NL, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest 2010; 120:343.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/108)
109.  [Krenger W, Holländer GA. The immunopathology of thymic GVHD. Semin Immunopathol 2008; 30:439.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/109)
110.  [Krenger W, Rossi S, Holländer GA. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation 2000; 69:2190.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/110)
111.  [Zakrzewski JL, Kochman AA, Lu SX, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med 2006; 12:1039.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/111)
112.  [Alpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood 2006; 107:2453.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/112)
113.  [Goldberg GL, Alpdogan O, Muriglan SJ, et al. Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation. J Immunol 2007; 178:7473.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/113)
114.  [Wada H, Masuda K, Satoh R, et al. Adult T-cell progenitors retain myeloid potential. Nature 2008; 452:768.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/114)
115.  [Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452:764.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/115)
116.  [Schwarz BA, Bhandoola A. Circulating hematopoietic progenitors with T lineage potential. Nat Immunol 2004; 5:953.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/116)
117.  [Serwold T, Ehrlich LI, Weissman IL. Reductive isolation from bone marrow and blood implicates common lymphoid progenitors as the major source of thymopoiesis. Blood 2009; 113:807.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/117)
118.  [Martin CH, Aifantis I, Scimone ML, et al. Efficient thymic immigration of B220+ lymphoid-restricted bone marrow cells with T precursor potential. Nat Immunol 2003; 4:866.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/118)
119.  [Arber C, BitMansour A, Sparer TE, et al. Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. Blood 2003; 102:421.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/119)
120.  [Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol 2009; 30:360.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/120)
121.  [Dudakov JA, Khong DM, Boyd RL, Chidgey AP. Feeding the fire: the role of defective bone marrow function in exacerbating thymic involution. Trends Immunol 2010; 31:191.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/121)
122.  [Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997; 160:91.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/122)
123.  [Gui J, Zhu X, Dohkan J, et al. The aged thymus shows normal recruitment of lymphohematopoietic progenitors but has defects in thymic epithelial cells. Int Immunol 2007; 19:1201.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/123)
124.  [Min D, Panoskaltsis-Mortari A, Kuro-O M, et al. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 2007; 109:2529.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/124)
125.  [Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002; 100:682.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/125)
126.  [Rossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood 2007; 109:3803.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/126)
127.  [Alpdogan O, Muriglan SJ, Eng JM, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest 2003; 112:1095.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/127)
128.  [Lu H, Zhao Z, Kalina T, et al. Interleukin-7 improves reconstitution of antiviral CD4 T cells. Clin Immunol 2005; 114:30.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/128)
129.  [Sempowski GD, Gooding ME, Liao HX, et al. T cell receptor excision circle assessment of thymopoiesis in aging mice. Mol Immunol 2002; 38:841.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/129)
130.  [Fry TJ, Moniuszko M, Creekmore S, et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101:2294.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/130)
131.  [Chu YW, Memon SA, Sharrow SO, et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004; 104:1110.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/131)
132.  [Andrew D, Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 2001; 166:1524.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/132)
133.  [Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/133)
134.  [Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012; 120:4882.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/134)
135.  [Fry TJ, Sinha M, Milliron M, et al. Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood 2004; 104:2794.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/135)
136.  [Kenins L, Gill JW, Boyd RL, et al. Intrathymic expression of Flt3 ligand enhances thymic recovery after irradiation. J Exp Med 2008; 205:523.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/136)
137.  [Wils EJ, Braakman E, Verjans GM, et al. Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation. J Immunol 2007; 178:3551.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/137)
138.  [Balciunaite G, Ceredig R, Massa S, Rolink AG. A B220+ CD117+ CD19- hematopoietic progenitor with potent lymphoid and myeloid developmental potential. Eur J Immunol 2005; 35:2019.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/138)
139.  [Ceredig R, Rauch M, Balciunaite G, Rolink AG. Increasing Flt3L availability alters composition of a novel bone marrow lymphoid progenitor compartment. Blood 2006; 108:1216.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/139)
140.  [Dixit VD, Yang H, Sun Y, et al. Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007; 117:2778.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/140)
141.  [Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev 2005; 205:72.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/141)
142.  [Carlo-Stella C, Di Nicola M, Milani R, et al. Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Exp Hematol 2004; 32:171.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/142)
143.  [Herasimtschuk AA, Westrop SJ, Moyle GJ, et al. Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines 2008; 6:7.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/143)
144.  [Napolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 2008; 118:1085.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/144)
145.  [Napolitano LA, Lo JC, Gotway MB, et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16:1103.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/145)
146.  [Plana M, Garcia F, Darwich L, et al. The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responses. Immunology 2011; 133:318.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/146)
147.  [Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. Aging Cell 2019; 18:e13028.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/147)
148.  [Dudakov JA, Hanash AM, Jenq RR, et al. Interleukin-22 drives endogenous thymic regeneration in mice. Science 2012; 336:91.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/148)
149.  [Pan B, Liu J, Zhang Y, et al. Acute ablation of DP thymocytes induces up-regulation of IL-22 and Foxn1 in TECs. Clin Immunol 2014; 150:101.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/149)
150.  [Dudakov JA, Mertelsmann AM, O'Connor MH, et al. Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease. Blood 2017; 130:933.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/150)
151.  [Wertheimer T, Velardi E, Tsai J, et al. Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. Sci Immunol 2018; 3.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/151)
152.  [Alpdogan O, Muriglan SJ, Kappel BJ, et al. Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 2003; 75:1977.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/152)
153.  [Chu YW, Schmitz S, Choudhury B, et al. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. Blood 2008; 112:2836.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/153)
154.  [Taguchi T, Takenouchi H, Matsui J, et al. Involvement of insulin-like growth factor-I and insulin-like growth factor binding proteins in pro-B-cell development. Exp Hematol 2006; 34:508.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/154)
155.  [Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/155)
156.  [Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105:865.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/156)
157.  [Alpdogan O, van den Brink MR. IL-7 and IL-15: therapeutic cytokines for immunodeficiency. Trends Immunol 2005; 26:56.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/157)
158.  [Chen J, Wang J, Li J, et al. Enhancement of cytotoxic T-lymphocyte response in aged mice by a novel treatment with recombinant AdIL-12 and wild-type adenovirus in rapid succession. Mol Ther 2008; 16:1500.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/158)
159.  [Chen T, Burke KA, Zhan Y, et al. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation. Exp Hematol 2007; 35:203.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/159)
160.  [Li L, Hsu HC, Stockard CR, et al. IL-12 inhibits thymic involution by enhancing IL-7- and IL-2-induced thymocyte proliferation. J Immunol 2004; 172:2909.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/160)
161.  [Eisenring M, vom Berg J, Kristiansen G, et al. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010; 11:1030.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/161)
162.  [Satoh-Takayama N, Lesjean-Pottier S, Vieira P, et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010; 207:273.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/162)
163.  [Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007; 25:238.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/163)
164.  [Chen X, Esplin BL, Garrett KP, et al. Retinoids accelerate B lineage lymphoid differentiation. J Immunol 2008; 180:138.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/164)
165.  [Nitta T, Ohigashi I, Nakagawa Y, Takahama Y. Cytokine crosstalk for thymic medulla formation. Curr Opin Immunol 2011; 23:190.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/165)
166.  [Lopes N, Vachon H, Marie J, Irla M. Administration of RANKL boosts thymic regeneration upon bone marrow transplantation. EMBO Mol Med 2017; 9:835.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/166)
167.  [Olsen NJ, Kovacs WJ. Effects of androgens on T and B lymphocyte development. Immunol Res 2001; 23:281.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/167)
168.  [Zoller AL, Kersh GJ. Estrogen induces thymic atrophy by eliminating early thymic progenitors and inhibiting proliferation of beta-selected thymocytes. J Immunol 2006; 176:7371.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/168)
169.  [Grimaldi CM, Jeganathan V, Diamond B. Hormonal regulation of B cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B cells at more than one developmental checkpoint. J Immunol 2006; 176:2703.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/169)
170.  [Kincade PW, Medina KL, Payne KJ, et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000; 175:128.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/170)
171.  [Viselli SM, Reese KR, Fan J, et al. Androgens alter B cell development in normal male mice. Cell Immunol 1997; 182:99.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/171)
172.  [Igarashi H, Kouro T, Yokota T, et al. Age and stage dependency of estrogen receptor expression by lymphocyte precursors. Proc Natl Acad Sci U S A 2001; 98:15131.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/172)
173.  [Medina KL, Garrett KP, Thompson LF, et al. Identification of very early lymphoid precursors in bone marrow and their regulation by estrogen. Nat Immunol 2001; 2:718.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/173)
174.  [Heng TS, Goldberg GL, Gray DH, et al. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol 2005; 175:2982.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/174)
175.  [Sutherland JS, Goldberg GL, Hammett MV, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175:2741.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/175)
176.  [Williams KM, Lucas PJ, Bare CV, et al. CCL25 increases thymopoiesis after androgen withdrawal. Blood 2008; 112:3255.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/176)
177.  [Greenstein BD, Fitzpatrick FT, Kendall MD, Wheeler MJ. Regeneration of the thymus in old male rats treated with a stable analogue of LHRH. J Endocrinol 1987; 112:345.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/177)
178.  [Olsen NJ, Watson MB, Henderson GS, Kovacs WJ. Androgen deprivation induces phenotypic and functional changes in the thymus of adult male mice. Endocrinology 1991; 129:2471.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/178)
179.  [Roden AC, Moser MT, Tri SD, et al. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol 2004; 173:6098.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/179)
180.  [Goldberg GL, King CG, Nejat RA, et al. Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. J Immunol 2009; 182:5846.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/180)
181.  [Erben RG, Eberle J, Stangassinger M. B lymphopoiesis is upregulated after orchiectomy and is correlated with estradiol but not testosterone serum levels in aged male rats. Horm Metab Res 2001; 33:491.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/181)
182.  [Ellis TM, Moser MT, Le PT, et al. Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. Int Immunol 2001; 13:553.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/182)
183.  [Erben RG, Raith S, Eberle J, Stangassinger M. Ovariectomy augments B lymphopoiesis and generation of monocyte-macrophage precursors in rat bone marrow. Am J Physiol 1998; 274:E476.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/183)
184.  [Masuzawa T, Miyaura C, Onoe Y, et al. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J Clin Invest 1994; 94:1090.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/184)
185.  [Dudakov JA, Goldberg GL, Reiseger JJ, et al. Withdrawal of sex steroids reverses age- and chemotherapy-related defects in bone marrow lymphopoiesis. J Immunol 2009; 182:6247.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/185)
186.  [Goldberg GL, Sutherland JS, Hammet MV, et al. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation 2005; 80:1604.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/186)
187.  [Schmitt TM, Zúñiga-Pflücker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 2002; 17:749.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/187)
188.  [Awong G, Herer E, Surh CD, et al. Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells. Blood 2009; 114:972.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/188)
189.  [Reimann C, Dal Cortivo L, Hacein-Bey-Abina S, et al. Advances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation. Immunotherapy 2010; 2:481.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/189)
190.  [Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol 2008; 26:453.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/190)
191.  [Holland AM, Zakrzewski JL, Goldberg GL, et al. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation in mouse and man. Semin Immunopathol 2008; 30:479.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/191)
192.  [Vago L, Oliveira G, Bondanza A, et al. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood 2012; 120:1820.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/192)
193.  [Gill J, Malin M, Holländer GA, Boyd R. Generation of a complete thymic microenvironment by MTS24(+) thymic epithelial cells. Nat Immunol 2002; 3:635.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/193)
194.  [Bennett AR, Farley A, Blair NF, et al. Identification and characterization of thymic epithelial progenitor cells. Immunity 2002; 16:803.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/194)
195.  [Depreter MG, Blair NF, Gaskell TL, et al. Identification of Plet-1 as a specific marker of early thymic epithelial progenitor cells. Proc Natl Acad Sci U S A 2008; 105:961.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/195)
196.  [Rossi SW, Chidgey AP, Parnell SM, et al. Redefining epithelial progenitor potential in the developing thymus. Eur J Immunol 2007; 37:2411.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/196)
197.  [Jenkinson WE, Bacon A, White AJ, et al. An epithelial progenitor pool regulates thymus growth. J Immunol 2008; 181:6101.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/197)
198.  [Bleul CC, Corbeaux T, Reuter A, et al. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 2006; 441:992.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/198)
199.  [Bonfanti P, Claudinot S, Amici AW, et al. Microenvironmental reprogramming of thymic epithelial cells to skin multipotent stem cells. Nature 2010; 466:978.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/199)
200.  [Chidgey AP, Seach N, Dudakov J, et al. Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches. Semin Immunopathol 2008; 30:457.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/200)
201.  [Seach N, Layton D, Lim J, et al. Thymic generation and regeneration: a new paradigm for establishing clinical tolerance of stem cell-based therapies. Curr Opin Biotechnol 2007; 18:441.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/201)
202.  [Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14:213.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/202)
203.  [Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 2010; 16:814.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/203)
204.  [Ott HC, Clippinger B, Conrad C, et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010; 16:927.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/204)
205.  [Petersen TH, Calle EA, Zhao L, et al. Tissue-engineered lungs for in vivo implantation. Science 2010; 329:538.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/205)
206.  [Seach N, Mattesich M, Abberton K, et al. Vascularized tissue engineering mouse chamber model supports thymopoiesis of ectopic thymus tissue grafts. Tissue Eng Part C Methods 2010; 16:543.](https://www.uptodate.cn/contents/zh-Hans/strategies-for-immune-reconstitution-following-allogeneic-hematopoietic-cell-transplantation/abstract/206)